Key result
Early RAAS blockade is recommended after dystrophinopathy diagnosis to slow myocardial fibrosis progression.
Why the study?
Dystrophin-deficient cardiomyopathy is the leading cause of death in dystrophinopathies, and targeting myocardial fibrosis is a major therapeutic goal, motivating a review of the role of the renin-angiotensin-aldosterone system.
Does RAAS blockade therapy prevent or delay myocardial fibrosis in patients with dystrophin-deficient cardiomyopathy?
Does RAAS blockade therapy prevent or delay myocardial fibrosis in patients with dystrophin-deficient cardiomyopathy?
Answers are grounded in this paper and cite their sources.
Preclinical evidence strongly supports the early initiation of RAAS blockade in patients with dystrophinopathies to prevent or delay myocardial fibrosis.
Dystrophin-deficient cardiomyopathy (DDC) is currently the leading cause of death in patients with dystrophinopathies. Targeting myocardial fibrosis (MF) has become a major therapeutic goal in order to prevent the occurrence of DDC. We aimed to review and summarize the current evidence about the role of the renin-angiotensin-aldosterone system (RAAS) in the development and perpetuation of MF in DCC. We conducted a comprehensive search of peer-reviewed English literature on PubMed about this subject. We found increasing preclinical evidence from studies in animal models during the last 20 years pointing out a central role of RAAS in the development of MF in DDC. Local tissue RAAS acts directly mainly through its main fibrotic component angiotensin II (ANG2) and its transducer receptor (AT1R) and downstream TGF-b pathway. Also, it modulates the actions of most of the remaining pro-fibrotic factors involved in DDC. Despite limited clinical evidence, RAAS blockade constitutes the most studied, available and promising therapeutic strategy against MF and DDC. Conclusion: Based on the evidence reviewed, it would be recommendable to start RAAS blockade therapy through angiotensin converter enzyme inhibitors (ACEI) or AT1R blockers (ARBs) alone or in combination with mineralocorticoid receptor antagonists (MRa) at the youngest age after the diagnosis of dystrophinopathies, in order to delay the occurrence or slow the progression of MF, even before the detection of any cardiovascular alteration.
No takes yet. Share an insight, caveat, or question.
Rodríguez‐González et al. (2020) conducted a review in Dystrophin-deficient cardiomyopathy. RAAS blockade (ACEI, ARBs, MRa) was evaluated. RAAS blockade therapy using ACEI or ARBs is recommended at the youngest age after dystrophinopathy diagnosis to delay or slow myocardial fibrosis progression.
Synapse has enriched 10 related papers. Consider them for comparative context: